AlphAIAlphAI — Financial news for AI agents
marketscreener.comOCT 22 min read$AZN

Daiichi, AstraZeneca enter clinical trial cooperation with Summit

Daiichi Sankyo and AstraZeneca will collaborate with Summit Therapeutics on a phase 3 trial of Datroway and ivonescimab for triple-negative breast cancer. Datroway targets Trop-2, while ivonescimab targets PD-1 and VEGF. Each company will contribute its drug and share trial costs, retaining commercial rights. Daiichi Sankyo closed down 1.2% at JPY2,709.00, and AstraZeneca rose 0.2% to 12,058.00 pence on Friday.

Original reporting
marketscreener.com
Published Oct 2, 2026, 9:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 9:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$AZN
Neutral
medium confidence
Mentioned
$AZN · $SMMT
Relevance
8/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$AZNNeutralMed
01

Why it matters

The partnership creates a multi‑company effort to develop a novel oncology therapy, potentially enhancing each firm's pipeline credibility and future revenue streams.

02

Market read

New oncology trial collaboration could influence pharma stocks and biotech valuations over the medium term.

03

What to watch

Regulatory timelines and potential competition from other antibody‑drug conjugates could limit upside.

Relevance 8/10Novelty 8/10Timing: today

Background

The article reports a newly announced clinical‑trial collaboration among Daiichi Sankyo, AstraZeneca and Summit Therapeutics, focusing on a Datroway‑ivonescimab combination for triple‑negative breast cancer.

Company-level read

Ticker impact

$AZNNeutralMedium confidence
Context

AstraZeneca entered a clinical‑trial partnership with Daiichi Sankyo and Summit Therapeutics to test Datroway plus ivonescimab.

Expected impact

likely slight upside as investors anticipate future data releases.

Evidence & confidence

AstraZeneca's large oncology exposure makes the trial material, but impact is long‑term.

$SMMTBullishMedium confidence
Context

Summit Therapeutics partnered with Daiichi Sankyo and AstraZeneca for a phase‑3 trial of Datroway and ivonescimab.

Expected impact

likely upward pressure as the market values the partnership.

Evidence & confidence

Small‑cap biotech often sees share price lift from high‑profile collaborations.

Market effects

Sector

Strengthens the oncology therapeutic pipeline narrative across pharma sector.

Regional

May boost Japanese pharma sentiment (Daiichi) and UK biotech outlook (AstraZeneca).

Global

Adds to global oncology trial pipeline, modest relevance to broader market.

Counterpoint

What could challenge this read

If early data are negative, the partnership could expose all three firms to reputational risk.

Key entities

  • Company
    Daiichi Sankyo Co Ltd

    Japanese pharma partner providing Datroway.

  • Company
    AstraZeneca PLC

    Global pharma partner providing ivonescimab.

  • Company
    Summit Therapeutics Inc

    Biopharma oncology company collaborating on the trial.

Read at source← All news

Also covered by

1 outlet

Related articles

OCT 2
$AZNMed

AstraZeneca and Daiichi Sankyo Partner with Summit Therapeutics to Study Datopotamab Deruxtecan and Ivonescimab

AstraZeneca, Daiichi Sankyo, and Summit Therapeutics will collaborate on a Phase 3 trial to study the combination of datopotamab deruxtecan and ivonescimab for treating triple-negative breast cancer (TNBC). The trial aims to evaluate the efficacy and safety of combining an antibody-drug conjugate with a bispecific immunotherapy. Datopotamab deruxtecan is approved for TNBC in the US, while ivonescimab is under FDA review for non-small cell lung cancer.

oncodaily.com2 min
OCT 2
$AZNMed

AstraZeneca and Daiichi Sankyo Team With Summit on Datroway Combination Trials

AstraZeneca (LON: AZN) and Daiichi Sankyo will collaborate with Summit Therapeutics to test Datroway with ivonescimab in multiple cancer types, including lung and breast cancers. The Phase III trial will focus on triple-negative breast cancer (TNBC). Each company retains rights to its own drug, and no financial terms were disclosed. AstraZeneca shares were down 0.50% at 11,972p.

asktraders.com2 min
OCT 2
$AZNMedAI 8/10

Daiichi Sankyo, AstraZeneca, Summit Partner On Datroway- Ivonescimab Cancer Studies

Daiichi Sankyo (4568.TS), AstraZeneca (AZN), and Summit Therapeutics (SMMT) will collaborate on clinical trials to evaluate Datroway (datopotamab deruxtecan) with ivonescimab for multiple solid tumors, starting with a Phase 3 study for triple-negative breast cancer. Datroway is an approved ADC, while ivonescimab is a novel bispecific antibody. Each company will contribute its medicine and share trial costs. SMMT's stock closed at $16.69, down 1.30%.

rttnews.com2 min
OCT 2
$SMMTMedAI 8/10

Summit Therapeutics Announces Clinical Trial Collaboration with

Summit Therapeutics (SMMT) partners with Daiichi Sankyo (4568) and AstraZeneca (AZN) to test ivonescimab with Datroway in breast and lung cancer trials. Phase III study in triple-negative breast cancer (TNBC) planned. Each company retains rights to their therapies. Ivonescimab is a novel bispecific antibody targeting PD-1 and VEGF, with ongoing Phase III trials in multiple cancers.

gurufocus.com3 min